Patent claims

1. Process for the preparation of a solid, orally administrable pharmaceutical composition comprising 5-chloro-*N*-({(5*S*)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (I) in hydrophilized form, characterized in that

   (a) first granules comprising the active compound (I) in hydrophilized form are prepared by moist granulation

   (b) and the granules are then converted into the pharmaceutical composition, if appropriate with addition of pharmaceutically suitable additives.

2. Process according to Claim 1, characterized in that the moist granulation method used is fluidized bed granulation.

3. Process according to Claim 1 or 2, characterized in that the active compound (I) is employed in crystalline form.

4. Process according to Claim 3, characterized in that the active compound (I) is employed in micronized form.

5. Process according to one of Claims 1 to 4, characterized in that the active compound (I) suspended in the granulating liquid is introduced into the moist granulation.

6. Process according to one of Claims 1 to 5, characterized in that the pharmaceutical composition is a tablet rapidly releasing the active compound (I).

7. Solid, orally administrable pharmaceutical composition prepared by the process according to Claim 1.

8. Solid, orally administrable pharmaceutical composition, comprising 5-chloro-*N*-({(5*S*)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene-carboxamide (I) in hydrophilized form.

9. Pharmaceutical composition according to Claim 8, comprising the active compound (I) in crystalline form.

10. Pharmaceutical composition according to Claim 9, comprising the active compound (I) in micronized form.

11. Pharmaceutical composition according to one of Claims 7 to 10, characterized in that the active compound (I) is present in a concentration of 1 to 60% based on the total mass of the formulation.

12. Pharmaceutical composition according to one of Claims 7 to 11, comprising sodium lauryl sulphate as a wetting agent.

13. Pharmaceutical composition according to Claim 12, comprising sodium lauryl sulphate in a concentration of 0.1 to 5%, based on the total mass.

14. Pharmaceutical composition according to one of Claims 7 to 13, comprising hydroxypropylmethylcellulose as a hydrophilic binding agent.

15. Pharmaceutical composition according to Claim 14, comprising hydroxypropylmethylcellulose in a concentration of 1 to 15%, based on the total mass.

16. Pharmaceutical composition according to one of Claims 7 to 15 in the form of a tablet.

17. Pharmaceutical composition according to Claim 16 in the form of a rapid-release tablet.

18. Pharmaceutical composition according to Claim 16 or 17, characterized in that the tablet is covered with a coating.

19. Use of the pharmaceutical composition according to one of Claims 7 to 18 for the prophylaxis and/or treatment of thromboembolic diseases.

20. Use of 5-chloro-*N*-({(5*S*)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (I) in hydrophilized form for preparing a medicament for the prophylaxis and/or treatment of thromboembolic diseases.

21. Process for the prophylaxis and/or treatment of thromboembolic diseases by administration of a pharmaceutical composition according to one of Claims 7 to 18.